Topoisomerase Inhibitors: A Review of their Therapeutic Potential in Cancer

Drugs

Volumn 49, Issue 1, 1995, Pages 11-19

  Sinha, Birandra K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ALKALOID; CAMPTOTHECIN; DAUNORUBICIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ENZYME INHIBITOR; EPIPODOPHYLLOTOXIN; ETOPOSIDE; GLUTATHIONE; GLYCOPROTEIN P; IRINOTECAN; PODOPHYLLOTOXIN; TENIPOSIDE; TOPOTECAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BRONCHOSPASM; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL SURVIVAL; CHILL; CLINICAL TRIAL; DIARRHEA; DRUG DETOXIFICATION; DRUG MECHANISM; DRUG TARGETING; DRUG TOXICITY; ENZYME INHIBITION; FEVER; GASTROINTESTINAL TOXICITY; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN CELL; HYPOTENSION; META ANALYSIS; MOUSE; MULTIDRUG RESISTANCE; NEUTROPENIA; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; VOMITING;

ANIMAL; ANTIBIOTICS, ANTHRACYCLINE; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; HUMAN; NEOPLASMS; PODOPHYLLOTOXIN; TOPOTECAN;

EID: 0028878831     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199549010-00002     Document Type: Article

References (53)

1. Interactions of some daunorubicin derivatives with deoxyribonucleic acid and their biological properties
2. Characteristics of the binding of the anticancer agents mitoxanthrone and amentantrone and related structures to deoxyribonucleic acids
3. Protein-associated DNA breaks in cells treated with adriamycin or ellipticin
4. Qualitative and quantitative aspects of intercalator-iriduced DNA strand breaks
5. Cleavage of DNA by mammalian topoisomerase II
6. Mechanism of antitumor drug action: Poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridnylamino)-methyanesulfon-m-anisidide
7. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II
8. Type I DNA topoisomerases
9. DNA topoisomerases: enzymes that catalyze the breaking and rejoining of DNA
10. DNA topoisomerases as targets for chemotherapy
11. Inhibitors of DNA topoisomerases
12. Mechanisms of resistance to drugs that inhibit DNA topoisomerases
13. Phosphorylation of mammalian DNA topoisomerase I and activation by protein kinase C
14. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II
15. Proliferation- and cell cycle-dependent differences in the expression of the p170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3t3 cells
16. Plant anti-tumor agents I: the isolation and structure of camptothecin, a novel alkaloidal leukemia and antitumor inhibitor from Camptotheca acuminata
17. Studies on oncolytic agents from natural sources: correlation of activity against animal tumors and clinical effectiveness
18. Camptothecin induces protein-linked DNA breaks via mammalian topoisomerase I
19. Preliminary pharmacological and clinical evaluation of camptothecin sodium (NSC 100880)
20. Topoisomerase I inhibitors: promising novel compounds
21. The current status of camptothecin and analogues as antitumor agents
22. Phase I and pharmacological studies of topotecan: a novel topoisomerase I inhibitor
23. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 10864), a new camptothecin analogue
24. Antitumor effects of CPT-11, a new derivative of camptothecin, against pleotropic drug-resistant tumors in vitro and in vivo.
25. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
26. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma
27. CPT-11: a new derivative of camptothecin for the treatment of refractory or relaspsed small cell lung cancer
28. Relationship of adriamycin to the DNA lesions induced in hypoxic and euoxic L1210
29. Two mechanisms of adriamycin-DNA interactions in L1210 cells
30. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II
31. Free radicals in anticancer drug pharmacology
32. Free radicals and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors
33. Resistance to multiple chemotherapeutic agents in human cancer cells
34. Comparison of cytotoxicity and DNA breakage activity of congeners of epipodophyllotoxin including VP-16,213 and VM-26: a quantitative structure-activity relationship
35. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action
36. Effects of VP-16-213 on the intracellular degradation of DNA in HeLa cells
37. Structure-activity relationship, cytotoxicity and topoisomerase II-mediated DNA cleavage induced by pendulum ring analogues of VP-16,213
38. Peroxidase-catalyzed metabolism of etoposide (VP-16,213) and covalent binding of reactive intermediates to cellular macromolecules
39. Characterization of free radicals produced during oxidation of etoposide (VP-16) and its catechol and quinone derivatives: an ESR study
40. Tyrosinase-induced free radical formation from VP-16,213: relationship to cytotoxicity
41. Iron-dependent hydroxyl radical formation and DNA damage from dihydroxy VP-16, a novel metabolite of VP-16
42. Copper-dependent oxy-radical mediated DNA damage from dihydroxy derivative of etoposide
43. P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug resistant tumor cell lines: pharmacokinetics and photoaffinity studies
44. Relationship of VP-16 to the classical multidrug resistance phenotype
45. Phase II study of α-hydroxy-2N-methylellipticinium acetate
46. Mitoxanthrone affects topoisomerase activities in human breast cancer cells
47. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
48. Multidrug resistanceassociated protein (MRP) overexpression and reduced sensitivity of topoisomerase II human breast carcinoma MCF-7 cell line selected for etoposide resistance
49. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation